Many currently available treatments for neurodegenerative diseases lack the ability to reach their target – the brain.

ArmaGen is evaluating therapeutic interventions for Alzheimer’s disease, Parkinson’s disease, Rett Syndrome and stroke that are designed to cross the blood-brain barrier.

Neurodegenerative Diseases